Viatris (VTRS) Share-based Compensation (2020 - 2026)
Viatris (VTRS) posted quarterly Share-based Compensation of $56.5 million for Q1 2026, up 92.83% year-over-year from $29.3 million in Q1 2025, and up 157.59% quarter-over-quarter from -$98.1 million in Q4 2025.
Viatris (VTRS) Share-based Compensation (2020 - 2026) Analysis & Trends
Viatris' Share-based Compensation history runs 7 years deep, the most recent figure standing at $56.5 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 92.83% year-over-year to $56.5 million; the TTM figure through Mar 2026 stood at $57.4 million (down 60.87% YoY), while the FY2025 annual figure was $30.2 million, down 79.33% from the prior year.
- Share-based Compensation for Q1 2026 stood at $56.5 million, up from -$98.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $94.9 million in Q3 2023, with the low at -$98.1 million in Q4 2025.
- The 5-year median for Share-based Compensation is $29.5 million (2022), against an average of $24.2 million.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation surged 708.33% in 2022, then slumped 392.91% in 2023.
- Viatris' Share-based Compensation stood at $29.6 million in 2022, then plunged by 392.91% to -$86.7 million in 2023, then soared by 207.04% to $92.8 million in 2024, then sank by 205.71% to -$98.1 million in 2025, then soared by 157.59% to $56.5 million in 2026.
- Business Quant data shows VTRS's Share-based Compensation at $56.5 million in Q1 2026, -$98.1 million in Q4 2025, and $36.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 31.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.40 Mn |
| Jun 30, 2026 | 30.40 Mn |
| Mar 31, 2026 | 56.50 Mn |
| Mar 31, 2026 | 56.50 Mn |
| Dec 31, 2025 | -98.10 Mn |
| Dec 31, 2025 | -98.10 Mn |
| Sep 30, 2025 | 36.00 Mn |
| Sep 30, 2025 | 36.00 Mn |
| Jun 30, 2025 | 63.00 Mn |
| Jun 30, 2025 | 63.00 Mn |
| Mar 31, 2025 | 29.30 Mn |
| Mar 31, 2025 | 29.30 Mn |
| Dec 31, 2024 | 92.80 Mn |
| Dec 31, 2024 | 92.80 Mn |
| Sep 30, 2024 | -28.10 Mn |
| Sep 30, 2024 | -28.10 Mn |
| Jun 30, 2024 | 52.70 Mn |
| Jun 30, 2024 | 52.70 Mn |
| Mar 31, 2024 | 28.70 Mn |
| Mar 31, 2024 | 28.70 Mn |